PK and Smoking Behaviour when Smoking different Cigarettes
Research type
Research Study
Full title
A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers when Smoking Cigarettes Containing Different Commonly Used Ingredients
IRAS ID
230150
Contact name
James K Ebajemito
Contact email
Sponsor organisation
British American Tobacco (Investments) Ltd
Duration of Study in the UK
0 years, 2 months, 24 days
Research summary
Smoking is a leading cause of numerous human diseases including lung cancer and cardiovascular diseases. Tobacco-related health risks are assumed to be due to repeated and sustained exposure to a range of smoke toxicants. Smoking cessation mitigates an individual’s relative risks of tobacco related disease. To this end, series of global regulatory and educational initiatives to persuade people not to smoke are ongoing. Despite these efforts, smoking rates in adult populations worldwide remain at 15-25%. Current scientific study and public policy debate, therefore, are concerned with whether public health gains could arise from regulation of existing, traditional combustible cigarette products.
For this purpose, the sponsor is planning this comparative clinical trial to assess the nicotine pharmacokinetics and smoking behaviour assessments on a suite of specifically manufactured Factory Made Cigarettes with different levels of a number of commonly used ingredients. Thy study will be performed at on site in the UK and will involve 48 smokers.REC name
HSC REC A
REC reference
17/NI/0117
Date of REC Opinion
30 Jun 2017
REC opinion
Favourable Opinion